AVITA Drug Patent Profile
✉ Email this page to a colleague
When do Avita patents expire, and when can generic versions of Avita launch?
Avita is a drug marketed by Mylan Pharms Inc and Mylan and is included in two NDAs.
The generic ingredient in AVITA is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the tretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Avita
A generic version of AVITA was approved as tretinoin by PADAGIS US on December 24th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AVITA?
- What are the global sales for AVITA?
- What is Average Wholesale Price for AVITA?
Summary for AVITA
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 1,254 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AVITA |
| Drug Sales Revenues: | Drug sales revenues for AVITA |
| What excipients (inactive ingredients) are in AVITA? | AVITA excipients list |
| DailyMed Link: | AVITA at DailyMed |
US Patents and Regulatory Information for AVITA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Pharms Inc | AVITA | tretinoin | CREAM;TOPICAL | 020404-003 | Jan 14, 1997 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | AVITA | tretinoin | GEL;TOPICAL | 020400-001 | Jan 29, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AVITA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Pharms Inc | AVITA | tretinoin | CREAM;TOPICAL | 020404-003 | Jan 14, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Mylan Pharms Inc | AVITA | tretinoin | CREAM;TOPICAL | 020404-003 | Jan 14, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AVITA
See the table below for patents covering AVITA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1331861 | METHODE ET COMPOSITIONS POUR AUGMENTER LA PENETRATION CUTANEE D'AGENTS PHARMACEUTIQUES ACTIFS (METHOD AND COMPOSITIONS FOR ENHANCING THE CUTANEOUS PENETRATION OF PHARMACOLOGICALLY ACTIVE AGENTS) | ⤷ Sign Up |
| Ireland | 882155 | ⤷ Sign Up | |
| European Patent Office | 0299758 | Compositions augmentant la pénétration cutanée d'agents pharmaceutiquement actifs. (Compositions for enhancing the cutaneous penetration of pharmacologically active agents.) | ⤷ Sign Up |
| Austria | 115553 | ⤷ Sign Up | |
| New Zealand | 225416 | CUTANEOUS PENETRATION-ENHANCING COMPOUNDS, PREPARATION AND COMPOSITIONS THEREOF, AND METHOD OF USE TOGETHER WITH AN ACTIVE AGENT | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AVITA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0617614 | C300043 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011 |
| 0617614 | 11/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011 |
| 1304992 | CR 2013 00053 | Denmark | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322 |
| 1304992 | 1390049-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322 |
| 1304992 | 92401 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
